title: Somatically mutated tumor antigens in the quest for a more efficacious patient-oriented immunotherapy of cancer.
abstract: Although cancer immunotherapy shows efficacy with adoptive T cell therapy (ACT) and antibody-based immune checkpoint blockade, efficacious therapeutic vaccination of cancer patients with tumor-associated antigens (TAAs) remains largely unmet. Current cancer vaccines utilize nonmutated shared TAAs that may have suboptimal immunogenicity. Experimental evidence underscores the strong immunogenicity of unique TAAs derived from somatically mutated cancer proteins, whose massive characterization has been precluded until recently by technical limitations. The development of cost-effective, high-throughput DNA sequencing approaches makes now possible the rapid identification of all the somatic mutations contained in a cancer cell genome. This method, combined with robust bioinformatics platforms for T cell epitope prediction and established reverse immunology approaches, provides us with an integrated strategy to identify patient-specific unique TAAs in a relatively short time, compatible with their potential use in the clinic. Hence, it is now for the first time possible to quantitatively define the patient's unique tumor antigenome and exploit it for vaccination, possibly in combination with ACT and/or immune checkpoint blockade to further increase immunotherapy efficacy.
authors.affiliation: Biocenter, Division for Bioinformatics, Innsbruck Medical University, Innrain 80, 6020, Innsbruck, Austria.
authors.forename: Zlatko
authors.initials: Z
authors.lastname: Trajanoski
authors.forename: Cristina
authors.initials: C
authors.lastname: Maccalli
authors.forename: Daniele
authors.initials: D
authors.lastname: Mennonna
authors.forename: Giulia
authors.initials: G
authors.lastname: Casorati
authors.forename: Giorgio
authors.initials: G
authors.lastname: Parmiani
authors.forename: Paolo
authors.initials: P
authors.lastname: Dellabona
mesh_terms: D000818:Animals; D000951:Antigens, Neoplasm / Q000235:genetics* / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D016246:Lymphocytes, Tumor-Infiltrating / Q000276:immunology*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D013601:T-Lymphocytes / Q000276:immunology* / Q000378:metabolism
chemical_list: D000951:Antigens, Neoplasm